Ubisol-Q10 (a nanomicellar water-soluble formulation of CoQ10) treatment inhibits Alzheimer-type behavioral and pathological symptoms in a double transgenic mouse (TgAPEswe, PSEN1dE9) model of Alzheimer’s disease

From National Research Council Canada

DOI	Resolve DOI: https://doi.org/10.3233/JAD-170275
Author	Search for: Muthukumaran, Krithika; Search for: Kanwar, Annie; Search for: Vegh, Caleb; Search for: Marginean, Alexandra; Search for: Elliott, Austin; Search for: Guilbeault, Nicholas; Search for: Badour, Alexander; Search for: Sikorska, Marianna¹; Search for: Cohen, Jerome; Search for: Pandey, Siyaram
Editor	Search for: Lanctôt, Krista
Name affiliation	National Research Council Canada. Human Health Therapeutics
Format	Text
Type	Article
Journal title	Journal of Alzheimer's Disease
ISSN	1387-2877 1875-8908
Pages	# of pages: 16
Subject	Alzheimer’s disease; amyloid-β plaques; CoQ10; long term memory; working memory
Abstract	Alzheimer’s disease (AD) is one of the most common neurodegenerative pathologies for which there are no effective therapies to halt disease progression. Given the increase in the incidence of this disorder, there is an urgent need for pharmacological intervention. Unfortunately, recent clinical trials produced disappointing results. Molecular mechanisms of AD are converging on the notion that mitochondrial dysfunction, oxidative stress, and accumulation of dysfunctional proteins are involved in AD pathology. Previously, we have shown that a water-soluble formulation of Coenzyme Q10 (Ubisol-Q10), an integral part of the electron transport chain, stabilizes mitochondria and prevents neuronal cell death caused by neurotoxins or oxidative stress both in vitro and in vivo. In this study, we evaluated the neuroprotective effects of Ubisol-Q10 treatment in double transgenic AD mice. In the present study, we report that providing Ubisol-Q10 in drinking water (at a dose of ∼6 mg/kg/day) reduced circulating amyloid-β (Aβ) peptide, improved long term memory, preserved working spatial memory, and drastically inhibited Aβ plaque formation in 18-month-old transgenic mice compared to an untreated transgenic group. Thus Ubisol-Q10 supplementation has the potential to inhibit the progression of neurodegeneration, leading to a better quality of life for humans suffering with AD.
Publication date	2017-11-16
Publisher	IOP
Language	English
Peer reviewed	Yes
NPARC number	23002525
Export citation	Export as RIS
Report a correction	Report a correction
Record identifier	78d76928-5428-4ad3-9c9b-e5781cb448f1
Record created	2017-11-22
Record modified	2020-03-16

Report a problem on this page

Date modified:: 2020-04-06